Invesco NASDAQ Biotech UCITS ETF (ETR:NBTK)

Assets	423.97M
Expense Ratio	0.40%
PE Ratio	23.74
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+53.31%

Volume	21,171
Open	64.28
Previous Close	64.06
Day's Range	64.02 - 65.51
52-Week Low	41.89
52-Week High	66.10
Beta	n/a
Holdings	1
Inception Date	Nov 6, 2014

About NBTK

Invesco NASDAQ Biotech UCITS ETF is an exchange traded fund launched by Source Investment Management Limited. The fund is managed by Assenagon Asset Management S.A. It invests in the public equity markets across the globe. The fund uses derivatives such as swaps to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sectors. It invests in the stocks of companies across all market capitalizations, with a minimum market capitalization of US $200 million. The fund seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing synthetic replication methodology. Invesco NASDAQ Biotech UCITS ETF was formed on November 6, 2014 and is domiciled in Ireland.

• Asset Class: Equity
• Category: Health Care
• Region: North America
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NBTK
• Provider: Invesco
• Index Tracked: NASDAQ / Biotechnology

Performance

NBTK had a total return of 53.31% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.75%.

Top Holdings

Name	Symbol	Weight
TRS NASDAQ Biotechnology TR USD	n/a	100.00%

Data Sources: S&P Global Market Intelligence, Twelve Data, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error